Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Inspiration Healthcare Group Plc LSE:IHC London Ordinary Share GB00BXDZL105 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.50 -3.16% 76.50 58,610 10:44:40
Bid Price Offer Price High Price Low Price Open Price
75.00 78.00 79.00 76.50 79.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 17.78 1.13 2.19 34.9 52
Last Trade Time Trade Type Trade Size Trade Price Currency
16:21:09 O 1,450 75.10 GBX

Inspiration Healthcare (IHC) Latest News (1)

More Inspiration Healthcare News
Inspiration Healthcare Investors    Inspiration Healthcare Takeover Rumours

Inspiration Healthcare (IHC) Discussions and Chat

Inspiration Healthcare Forums and Chat

Date Time Title Posts
10/11/202012:40Inspiration Healthcare Group plc478
13/5/202008:45IHC Inspiration Health - Ventilators & PPE in the fight against COVID-19160
02/3/201201:13India Hospitality Corporation129
06/4/200907:44IHC - Significant Undervaluation8

Add a New Thread

Inspiration Healthcare (IHC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-12-01 16:21:0975.101,4501,088.95O
2020-12-01 16:17:0677.822,5591,991.41O
2020-12-01 16:06:1175.10724543.72O
2020-12-01 15:44:0477.821,000778.20O
2020-12-01 14:25:3478.001,282999.96O
View all Inspiration Healthcare trades in real-time

Inspiration Healthcare (IHC) Top Chat Posts

DateSubject
01/12/2020
08:20
Inspiration Healthcare Daily Update: Inspiration Healthcare Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker IHC. The last closing price for Inspiration Healthcare was 79p.
Inspiration Healthcare Group Plc has a 4 week average price of 70p and a 12 week average price of 62p.
The 1 year high share price is 89.50p while the 1 year low share price is currently 57p.
There are currently 67,973,609 shares in issue and the average daily traded volume is 41,975 shares. The market capitalisation of Inspiration Healthcare Group Plc is £51,999,810.89.
27/10/2020
15:38
lammylover: Fabulous rise today - tipped by Midas (Daily Mail) a couple of week ago; then Moneyweek tipped, then Investors Chronicle today. Simon Thompson Target is for 105p - for early 2021 on FY results. I've top sliced a few today, as my portfolio was top heavy with IHC. Still keeping a very significant number though with target 100p+ Well done all holders who kept the faith with IHC despite the MMs walking the share price down at every opportunity! It makes a nice change to see this share rising strongly today. Rich
06/10/2020
07:28
rivaldo: Cheers WGT, appreciated - that must have been a while ago :o)) Cenkos have increased this year's forecast to diluted EPS of 4.9p, with £5m net cash at the year end. They also state that there's between 30% and 65% upside to the overnight share price based on the usual multiples, so the high end would see the share price up to 102p.
11/6/2020
08:30
hastings: Good to enjoy your company as always Rivaldo! Not sure if this will be of interest or not, but I penned this piece on IHC for the Mike Walters board early May. It may touch on a few things that haven't been mentioned elsehwere. No share, or very rarely, ticks all the boxes, but when a number of factors come together positively it is usually worth delving deeper and considering its investment merits. The first thing to note with IHC is that it operates in a market that is in many ways somewhat insulated from the effects of any impending recession or the inevitable downturn. That is because the company is a supplier of life saving medical devices in areas of neonatal intensive care and patient warming, which by their nature are pretty much non negotiable, perhaps even more so in these strange times. More on that in a while, but in addition to operating in what can be seen as a constant market place, IHC is firstly profitable, holds net cash of £4.5m, stands on a PEG of 0.42 and in its most recent results delivered impressive organic growth of 12%. There are a few potential negatives if you use the likes of Stockopedia or other platforms, but as I always like to add, it is worth remembering that such tools are largely lagging, working on historic numbers/data and often do not take into account the most recent events or data related to a company's prospects. Admittedly though, at the current price of 62p the shares trading on a forward PER of 14 probably look priced about right at present, particularly in such uncertain times. However, IHC appears to have some really excellent growth prospects and it is interesting to note that it has, over the last few years cemented a very strong relationship with the NHS as demonstrated by recent news which is now assisting the company in further delivering on its business plan. Regarding the recent news here, having announced on the 16th March that it was to supply ventilators to the NHS for the fight against Covid19 which was a positive in itself, it subsequently went on to announce additional orders for other medical equipment and further ventilators to the value of £4m. Then, last Friday, confirming that a first batch of ventilators had arrived in the UK the company added that it had extended its 24 hour helpline facility to clinical staff at all UK hospitals in relation to access to qualified personnel employed directly by IHC relating specifically to the ventilators. Broker Cenkos described the news as a hugely significant announcement for the company and highlights the close relationship the team has developed with both the NHS and its commercial partners. Further positive news was also forthcoming last month too concerning a collaboration with Genedrive regarding its anibiotic induced hearing loss test across the UK and Ireland. The companies also expect to expand the scope of the contract over time to engage Inspiration Healthcare's network of more than 50 neonatal-focused sub-distributors around the world. The Genedrive MT-RNR1 AIHL test is the world's first point-of-care genetic test designed for use in a neonatal intensive care setting. The test screens newborns for a genetic mutation called mt-RNR1 that can cause lifelong and irreversible deafness to a child upon administration of certain antibiotics. “Our agreement with Inspiration Healthcare combines genedrive's innovative first-to-market AIHL product, with a thought-leading healthcare company with a specialist emphasis on neonatal care,” David Budd, Genedrive's chief executive officer said in a statement. “Inspiration Healthcare has a strong track record in the introduction of new technologies and over many years they have developed an extensive network of key opinion leaders that will be very beneficial as we bring the Genedrive AIHL test to market together,” he added. Neil Campbell, the CEO of Inspiration Healthcare, said the company was “delighted to be able to work with genedrive”. “Our focus has always been products that can have a profound effect on the patient outcome and we look forward to working with genedrive to make this test the standard of care in the UK and the wider neonatal community around the world,” he added. Having also released its full year results last month, revenue for full year 2020 came out at £17.8m which saw the critical care market provide for £11.4m of sales which enjoyed a 7% increase where its AlphaCore5 warming system for patients in neonatal intensive care units was a key driver. Sales for Operating Theatres came out at £1.7m whilst Home Healthcare revenues jumped by 50% year on year which now sees the company distributing Micrel parenteral feeding products. With a decent mix of its own brands complementing others, both of which are focused on disruptive innovative technologies the company looks well set to continue on a growth trajectory which is likely to boost impressive organic growth by timely made acquisitions. To this end, it made its first purchase last year in the form of Viomedix for £4m (placing) and given the prevailing climate, this looks to be an excellent acquisition as the acquired business provides innovative solutions to resolving patient problems in the respiratory care market. What's more, it is very much specialised in the designing and supplying of disposable respiratory products and sterile medical consumables including breathing circuits, perforators and surgical markers. Returning to the neonatal area where the company is very much focused it is worth noting that according to various industry reports, particularly that of Grand View Research Inc, the fetal and neonatal care equipment market is expected to be worth some $10.6b by 2026 based on an expanding compounded annual growth rate of 6.9%. Although IHC is already making sound progress in this sector it isn't resting on its laurels and has, within its pipeline of novel products/devices a very recently US (recently patent granted) project named Project Wave. The company entered into a licence agreement in 2019 with a major US West Coast University to develop what is described as a new ground breaking device that will target apnea of prematurity which is defined as the cessation of breathing by a premature infant that lasts for more than 20 seconds and is accompanied by often very serious complications. Treatments that have been used for almost three decades have raised concerns of long term negative effects, so IHC looks to have identified a positive health and commercial opening with what is described as a ground breaking respiratory device that is now expected to move quickly to trials this summer. Research at the university involved has found that the device could help to normalise an infant’s breathing rate and reduce apnoea associated with prematurity. Inspiration Healthcare have indicated that over 1.5 million babies suffer from apnoea of prematurity (or require respiratory support) each year, indicating a potential market size for Project Wave of over $60m per year. A significant feature of Inspiration Healthcare’s business strategy is, according to broker Cenkos its focus on the neonatal intensive care market. This is an essential, non-elective market where – premature and unwell newborns in western markets will be treated regardless of economic pressures. The company, which was once a pure distributor of medical equipment has now grown into a fully integrated medtech technology company within the neonatal intensive care setting which doesn't appear to be reflected in its market valuation where many still seem to perceive it as pure distribution play. In that context, the current market cap of £24m looks pretty modest, particularly in light of an increasing proportion of Inspiration’s revenues (46%) and profits being generated from the sale of equipment under its own brand. This provides the company with greater product control and the generation of improved margins. With an already established footprint across the UK and Ireland the company will look to expand that further whilst it is also actively looking to increase its presence across international markets which at present only accounts for circa 12% of revenue. Looking ahead to the financial year in play, Cenkos is expecting revenue of £20.4m, Ebitda £2.83m and adjusted pre-tax profits of £1.88m providing for EPS of 4.2p aND net cash is expected to improve to £4.7m. The 52 week range of the shares is a low of 55p against a high of 90p, which suggests that if future progress is maintained as expected, alongside another timely acquisition, then investors eyeing the medium-longer term could be suitably rewarded. Obviously there are some big name players also operating in the space but given the number of active smaller players gives it something of a fragmented look suggesting a ripe environment for consolidation. IHC has clearly made solid progress in recent years and the management appear sound with a conservative approach as revenues largely organic driven have improved from £9.5m in 2015 (listing year, via reverse into (Inditherm) up to the recently reported £17.8m. Pre-tax profits have also in the last three years begun to build momentum and the board has already stated an intention to commence a progressive dividend policy
06/5/2020
10:58
hastings: Posted on the other thread too. I haven't had time to digest fully the new broker note this morning, but suffice to say that a continued positive performance on the back of this mornings update should result in an upgrade. Anyway, penned this for interest, was earmarked for my column but I'll probably write that again now. No share, or very rarely does one tick all the boxes, but when a number of factors come together positively, it is usually worth delving deeper and considering its investment merits. The first thing to note with IHC is that it operates in a market that is in many ways somewhat insulated from the effects of any impending recession or the inevitable downturn. That is because the company is a supplier of life saving medical devices in areas of neonatal intensive care and patient warming, which by their nature are pretty much non negotiable, perhaps even more so in these strange times. More on that in a while, but in addition to operating in what can be seen as a constant market place, IHC is firstly profitable, holds net cash of £4.5m, stands on a PEG of 0.42 and in its most recent results delivered impressive organic growth of 12%. There are a few potential negatives if you use the likes of Stockopedia or other platforms, but as I always like to add, it is worth remembering that such tools are largely lagging, working on historic numbers/data and often do not take into account the most recent events or data related to a company's prospects. Admittedly though, at the current price of 62p the shares trading on a forward PER of 14 probably look priced about right at present, particularly in such uncertain times. However, IHC appears to have some really excellent growth prospects and it is interesting to note that it has, over the last few years cemented a very strong relationship with the NHS as demonstrated by recent news which is now assisting the company in further delivering on its business plan. Regarding the recent news here, having announced on the 16th March that it was to supply ventilators to the NHS for the fight against Covid19 which was a positive in itself, it subsequently went on to announce additional orders for other medical equipment and further ventilators to the value of £4m. Then, last Friday, confirming that a first batch of ventilators had arrived in the UK the company added that it had extended its 24 hour helpline facility to clinical staff at all UK hospitals in relation to access to qualified personnel employed directly by IHC relating specifically to the ventilators. Broker Cenkos described the news as a hugely significant announcement for the company and highlights the close relationship the team has developed with both the NHS and its commercial partners. Further positive news was also forthcoming last month too concerning a collaboration with Genedrive regarding its anibiotic induced hearing loss test across the UK and Ireland. The companies also expect to expand the scope of the contract over time to engage Inspiration Healthcare's network of more than 50 neonatal-focused sub-distributors around the world. The Genedrive MT-RNR1 AIHL test is the world's first point-of-care genetic test designed for use in a neonatal intensive care setting. The test screens newborns for a genetic mutation called mt-RNR1 that can cause lifelong and irreversible deafness to a child upon administration of certain antibiotics. “Our agreement with Inspiration Healthcare combines genedrive's innovative first-to-market AIHL product, with a thought-leading healthcare company with a specialist emphasis on neonatal care,” David Budd, Genedrive's chief executive officer said in a statement. “Inspiration Healthcare has a strong track record in the introduction of new technologies and over many years they have developed an extensive network of key opinion leaders that will be very beneficial as we bring the Genedrive AIHL test to market together,” he added. Neil Campbell, the CEO of Inspiration Healthcare, said the company was “delighted to be able to work with genedrive”. “Our focus has always been products that can have a profound effect on the patient outcome and we look forward to working with genedrive to make this test the standard of care in the UK and the wider neonatal community around the world,” he added. Having also released its full year results last month, revenue for full year 2020 came out at £17.8m which saw the critical care market provide for £11.4m of sales which enjoyed a 7% increase where its AlphaCore5 warming system for patients in neonatal intensive care units was a key driver. Sales for Operating Theatres came out at £1.7m whilst Home Healthcare revenues jumped by 50% year on year which now sees the company distributing Micrel parenteral feeding products. With a decent mix of its own brands complementing others, both of which are focused on disruptive innovative technologies the company looks well set to continue on a growth trajectory which is likely to boost impressive organic growth by timely made acquisitions. To this end, it made its first purchase last year in the form of Viomedix for £4m (placing) and given the prevailing climate, this looks to be an excellent acquisition as the acquired business provides innovative solutions to resolving patient problems in the respiratory care market. What's more, it is very much specialised in the designing and supplying of disposable respiratory products and sterile medical consumables including breathing circuits, perforators and surgical markers. Returning to the neonatal area where the company is very much focused, it is worth noting that according to various industry reports, particularly that of Grand View Research Inc, the fetal and neonatal care equipment market is expected to be worth some $10.6b by 2026 based on an expanding compounded annual growth rate of 6.9%. Although IHC is already making sound progress in this sector it isn't resting on its laurels and has, within its pipeline of novel products/devices a very recently US (recently patent granted) project named Project Wave. The company entered into a licence agreement in 2019 with a major US West Coast University to develop what is described as a new ground breaking device that will target apnea of prematurity which is defined as the cessation of breathing by a premature infant that lasts for more than 20 seconds and is accompanied by often very serious complications. Treatments that have been used for almost three decades have raised concerns of long term negative effects, so IHC looks to have identified a positive health and commercial opening with what is described as a ground breaking respiratory device that is now expected to move quickly to trials this summer. Research at the university involved has found that the device could help to normalise an infant’s breathing rate and reduce apnoea associated with prematurity. Inspiration Healthcare have indicated that over 1.5 million babies suffer from apnoea of prematurity (or require respiratory support) each year, indicating a potential market size for Project Wave of over $60m per year. A significant feature of Inspiration Healthcare’s business strategy is, according to broker Cenkos a focus on the neonatal intensive care market. This is an essential, non-elective market where – premature and unwell newborns in western markets will be treated regardless of economic pressures. The company, which was once a pure distributor of medical equipment has now grown into a fully integrated medtech technology company within the neonatal intensive care setting, which doesn't appear to be reflected in its market valuation where many still seem to perceive it as pure distribution play. In that context, the current market cap of £24m looks pretty modest, particularly in light of an increasing proportion of Inspiration’s revenues (46%) and profits being generated from the sale of equipment under its own brand. This provides the company with greater product control and the generation of improved margins. With an already established footprint across the UK and Ireland the company will look to expand that further whilst it is also actively looking to increase its presence across international markets which at present only accounts for circa 12% of revenue. Looking ahead to the financial year in play, Cenkos is expecting revenue of £20.4m, Ebitda £2.83m and adjusted pre-tax profits of £1.88m providing for EPS of 4.2p aND net cash is expected to improve to £4.7m. The 52 week range of the shares is a low of 55p against a high of 90p, which suggests that if future progress is maintained as expected, alongside another timely acquisition, then investors eyeing the medium-longer term could be suitably rewarded. Obviously there are some big name players also operating in the space but given the number of active smaller players gives it something of a fragmented look, suggesting a ripe environment for consolidation. IHC has clearly made solid progress in recent years and the management appear sound with a conservative approach, as revenues largely organic driven have improved from £9.5m in 2015 (listing year, via reverse into (Inditherm) up to the recently reported £17.8m. Pre-tax profits have also in the last three years begun to build momentum and the board has already stated an intention to commence a progressive dividend policy as of next year.
06/5/2020
09:08
hastings: I haven't had time to digest fully the new broker note this morning, but suffice to say that a continued positive performance on the back of this mornings update should result in an upgrade. Anyway, penned this for interest, was earmarked for my column but I'll probably write that again now. No share, or very rarely does one tick all the boxes, but when a number of factors come together positively, it is usually worth delving deeper and considering its investment merits. The first thing to note with IHC is that it operates in a market that is in many ways somewhat insulated from the effects of any impending recession or the inevitable downturn. That is because the company is a supplier of life saving medical devices in areas of neonatal intensive care and patient warming, which by their nature are pretty much non negotiable, perhaps even more so in these strange times. More on that in a while, but in addition to operating in what can be seen as a constant market place, IHC is firstly profitable, holds net cash of £4.5m, stands on a PEG of 0.42 and in its most recent results delivered impressive organic growth of 12%. There are a few potential negatives if you use the likes of Stockopedia or other platforms, but as I always like to add, it is worth remembering that such tools are largely lagging, working on historic numbers/data and often do not take into account the most recent events or data related to a company's prospects. Admittedly though, at the current price of 62p the shares trading on a forward PER of 14 probably look priced about right at present, particularly in such uncertain times. However, IHC appears to have some really excellent growth prospects and it is interesting to note that it has, over the last few years cemented a very strong relationship with the NHS as demonstrated by recent news which is now assisting the company in further delivering on its business plan. Regarding the recent news here, having announced on the 16th March that it was to supply ventilators to the NHS for the fight against Covid19 which was a positive in itself, it subsequently went on to announce additional orders for other medical equipment and further ventilators to the value of £4m. Then, last Friday, confirming that a first batch of ventilators had arrived in the UK the company added that it had extended its 24 hour helpline facility to clinical staff at all UK hospitals in relation to access to qualified personnel employed directly by IHC relating specifically to the ventilators. Broker Cenkos described the news as a hugely significant announcement for the company and highlights the close relationship the team has developed with both the NHS and its commercial partners. Further positive news was also forthcoming last month too concerning a collaboration with Genedrive regarding its anibiotic induced hearing loss test across the UK and Ireland. The companies also expect to expand the scope of the contract over time to engage Inspiration Healthcare's network of more than 50 neonatal-focused sub-distributors around the world. The Genedrive MT-RNR1 AIHL test is the world's first point-of-care genetic test designed for use in a neonatal intensive care setting. The test screens newborns for a genetic mutation called mt-RNR1 that can cause lifelong and irreversible deafness to a child upon administration of certain antibiotics. “Our agreement with Inspiration Healthcare combines genedrive's innovative first-to-market AIHL product, with a thought-leading healthcare company with a specialist emphasis on neonatal care,” David Budd, Genedrive's chief executive officer said in a statement. “Inspiration Healthcare has a strong track record in the introduction of new technologies and over many years they have developed an extensive network of key opinion leaders that will be very beneficial as we bring the Genedrive AIHL test to market together,” he added. Neil Campbell, the CEO of Inspiration Healthcare, said the company was “delighted to be able to work with genedrive”. “Our focus has always been products that can have a profound effect on the patient outcome and we look forward to working with genedrive to make this test the standard of care in the UK and the wider neonatal community around the world,” he added. Having also released its full year results last month, revenue for full year 2020 came out at £17.8m which saw the critical care market provide for £11.4m of sales which enjoyed a 7% increase where its AlphaCore5 warming system for patients in neonatal intensive care units was a key driver. Sales for Operating Theatres came out at £1.7m whilst Home Healthcare revenues jumped by 50% year on year which now sees the company distributing Micrel parenteral feeding products. With a decent mix of its own brands complementing others, both of which are focused on disruptive innovative technologies the company looks well set to continue on a growth trajectory which is likely to boost impressive organic growth by timely made acquisitions. To this end, it made its first purchase last year in the form of Viomedix for £4m (placing) and given the prevailing climate, this looks to be an excellent acquisition as the acquired business provides innovative solutions to resolving patient problems in the respiratory care market. What's more, it is very much specialised in the designing and supplying of disposable respiratory products and sterile medical consumables including breathing circuits, perforators and surgical markers. Returning to the neonatal area where the company is very much focused, it is worth noting that according to various industry reports, particularly that of Grand View Research Inc, the fetal and neonatal care equipment market is expected to be worth some $10.6b by 2026 based on an expanding compounded annual growth rate of 6.9%. Although IHC is already making sound progress in this sector it isn't resting on its laurels and has, within its pipeline of novel products/devices a very recently US (recently patent granted) project named Project Wave. The company entered into a licence agreement in 2019 with a major US West Coast University to develop what is described as a new ground breaking device that will target apnea of prematurity which is defined as the cessation of breathing by a premature infant that lasts for more than 20 seconds and is accompanied by often very serious complications. Treatments that have been used for almost three decades have raised concerns of long term negative effects, so IHC looks to have identified a positive health and commercial opening with what is described as a ground breaking respiratory device that is now expected to move quickly to trials this summer. Research at the university involved has found that the device could help to normalise an infant’s breathing rate and reduce apnoea associated with prematurity. Inspiration Healthcare have indicated that over 1.5 million babies suffer from apnoea of prematurity (or require respiratory support) each year, indicating a potential market size for Project Wave of over $60m per year. A significant feature of Inspiration Healthcare’s business strategy is, according to broker Cenkos a focus on the neonatal intensive care market. This is an essential, non-elective market where – premature and unwell newborns in western markets will be treated regardless of economic pressures. The company, which was once a pure distributor of medical equipment has now grown into a fully integrated medtech technology company within the neonatal intensive care setting, which doesn't appear to be reflected in its market valuation where many still seem to perceive it as pure distribution play. In that context, the current market cap of £24m looks pretty modest, particularly in light of an increasing proportion of Inspiration’s revenues (46%) and profits being generated from the sale of equipment under its own brand. This provides the company with greater product control and the generation of improved margins. With an already established footprint across the UK and Ireland the company will look to expand that further whilst it is also actively looking to increase its presence across international markets which at present only accounts for circa 12% of revenue. Looking ahead to the financial year in play, Cenkos is expecting revenue of £20.4m, Ebitda £2.83m and adjusted pre-tax profits of £1.88m providing for EPS of 4.2p aND net cash is expected to improve to £4.7m. The 52 week range of the shares is a low of 55p against a high of 90p, which suggests that if future progress is maintained as expected, alongside another timely acquisition, then investors eyeing the medium-longer term could be suitably rewarded. Obviously there are some big name players also operating in the space but given the number of active smaller players gives it something of a fragmented look, suggesting a ripe environment for consolidation. IHC has clearly made solid progress in recent years and the management appear sound with a conservative approach, as revenues largely organic driven have improved from £9.5m in 2015 (listing year, via reverse into (Inditherm) up to the recently reported £17.8m. Pre-tax profits have also in the last three years begun to build momentum and the board has already stated an intention to commence a progressive dividend policy as of next year.
05/5/2020
19:09
vprt: Hi troutisout: I'm not an expert on investment trusts and have not spent time pondering such "what if" questions (as I don't own MINI) - others might have better views on that. But I don't think an annual redemption clause is a standard thing, and possibly quite unusual. The point is that I believe there is quite some risk of IHC shares being sold in the market, but it is unclear how many, and how gently/slowly or brutally/quickly this will happen. Miton give themselves lots of leeway on the "how", as the following extract from the RNS illustrates. (It seems to me that they are trying to shelter long term holders i.e. those who are not redeeming by letting the "Redemption Pool" take most of the pain from any low-valued sales, if they choose to carve up the assets in advance in that way): "Shareholders submitting valid requests for the redemption of Ordinary Shares will have their shares redeemed at the Redemption Price which is calculated on either of the following bases: I. The Directors may elect to divide each of the Company's portfolio holdings in proportion to the percentage of shareholders opting for redemption and set them aside in a Redemption Pool to be sold via the stock market. When complete, the realisation proceeds after deduction of costs would be distributed to shareholders pro rata. It should be noted that the liquidation of a Redemption Pool can be expected to take some weeks or months, and the final capital sum may not amount to the initial valuation of the Redemption Pool. As highlighted in the Company's Half Year Report, published on 13 December 2019, shareholders should note that this is the method most likely to be used; or II. If the percentage of the Company's shares that opt for redemption is a modest proportion of the Company the Directors can set a Redemption Price that is equal to the Net Asset Value per Ordinary Share (including current period revenue) (the "Dealing Value") prevailing on the last business day prior to the Redemption Point. The Directors may elect, at their absolute discretion, to calculate the Redemption Price on the bases set out above, or the Company may arrange for such shares to be sold in the market at the Dealing Value (subject to the Directors' discretion). At the date of writing the share price of the Company is standing at a discount to the Net Asset Value, and if this was the case at the Redemption Point, then it is unlikely that there would be willing buyers of the redeemed shares at the Dealing Value. The Directors are minded to approve all redemption requests unless there are exceptional reasons why this would be contrary to the interests of all shareholders. " ...
07/4/2020
15:38
lammylover: I think its just PIs expecting too much. Those who bought in around mid 60s, expected instant surge in share price on additional orders. People are not prepared to wait a week or two for results to come out (approx. 20th April, by my reckoning) and move money elsewhere as every other share seems to have surged in price the last 2 days. Happy to hold for results - lets face it, IHC revenue must be up on increased demand and EBITDA the same. I can't see a reduction in demand for medical items in the near future, the only risk is if they can't supply enough due to global demand. The current share price doesn't include any uplift for the £4m ventilator order - in fact share price hit 72p before the 2 orders in March. Just my take on things - patience is a virtue! The market transfers money from the impatient to the patient - Warren Buffett
07/4/2020
12:57
geovest: Don't blame the MM's or institutional investors. It is probably private investors bailing out because the share price didn't double as they expected, now they are selling out at a loss. MM's and II's know how companies are valued, most PI's don't. A simple way to look at it is: The value of a company is the discounted cashflow of all future earnings. A huge £4m order for ventilators is a one-off event, it changes the value of the company only to the extent of the one-off profit. As they act as distributor, their profit margin is probably below 10%. If we are generous, that's £400k profit. The current market Cap for the company is £25m. So, this order, if delivered in full, would increase that by £400k or 1.6%. The share price before the announcement was 64p. The order could only ever have added 1p to the share price, but unrealistic expectations and lack of understanding pushed the price up to nearly 90p. It is probably those shareholders now selling.... Having said that, still a good company with potential value if you take at least a 5 year view.
06/4/2020
17:23
lammylover: Share price at 64p is WAY BELOW the share price reached when they announced the last results being ahead of expectations - price then rose to 72p. It appears that there is still a large seller selling off blocks of shares into any share price rise and effectively keeping the price down. But also there are lots of large buys going through sub 66p. At current price of 64p, there is nothing factored in for the £5m order from NHS received in March. Quite why the large seller is offloading, is anyone's guess? All I can say is that the next update on results should be around 20th April (based on last 2 years RNS trade updates) and I can't see it being anything but positive. Even if the NHS ventilators are still in transit, we know the order is good and its almost certain that other orders from NHS and other countries since the CV outbreak will be significantly larger than normal. Summary = absolute bargain at 64p; however its a crazy market out there!! Rich
03/4/2020
07:36
lammylover: IHC year share price range is 57.1p to 89.9p. The share price reached 72.65p in January on RNS detailing year end information including "ahead of market expectations" results. Since then they have picked up a £4.0m order for ventillators from NHS. Share price rose to 89.9p on this news. Subsequently price has slipped back on low volume and no news. This company supplies all manner of medical supplies, not just ventillators. At this time of unprecedented demand, why on earth would you think that sales would fall and share price be at 50p??? You should do yourself a favour and buy today at 64.5p and thank me when the results come in! Rich
Inspiration Healthcare share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IHC
Inspiratio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201202 04:35:43